Identification

Name
Ivacaftor
Accession Number
DB08820  (DB05989)
Type
Small Molecule
Groups
Approved
Description

Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF) in patients aged 2 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes [5, 6]. As a result, CF patients produce a thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition [8].

Use of Ivacaftor has been shown to both improve CF symptoms and modulate underlying disease pathology. This is achieved by potentiating the channel opening probability (or gating) of CFTR protein in patients with impaired gating mechanisms. This is in contrast to Lumacaftor, another CF medication, that functions by preventing misfolding of the CFTR protein and thereby results in increased processing and trafficking of mature protein to the cell surface. Results from clinical trials indicated that treatment with ivacaftor results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, increased weight gain, and improvements in CF symptoms [FDA Label]. This data has been heavily scrutinized, however, with clinical trials showing only modest improvements despite a hefty yearly cost of $259,000 for Orkambi (lumacaftor/ivacaftor) [11].

A wide variety of CFTR mutations correlate to the Cystic Fibrosis phenotype and are associated with differing levels of disease severity. The most common mutation, affecting approximately 70% of patients with CF worldwide, is known as F508del-CFTR or delta-F508 (ΔF508), in which a deletion in the amino acid phenylalanine at position 508 results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes [7]. Ivacaftor as monotherapy has failed to show a benefit for patients with delta-F508 mutations, most likely due to insufficient amount of protein available at the cell membrane for interaction and potentiation by the drug[10]. The next most common mutation, G551D, affecting 4-5% of CF patients worldwide is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening and closing mechanisms of the channel are altered [9]. Ivacaftor is indicated for the management of CF in patients with this second type of mutation, as it binds to and potentiates the channel opening ability of CFTR proteins on the cell membrane [9].

Although ivacaftor has not shown any significant improvements in patients with the delta-F508 mutation, it has shown significant improvements (>10% increase in FEV1 from baseline) in lung function for the following mutations: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, and G1349D [FDA Label]. This list was expanded by the FDA in May 2017 from 10 to 33 to accomodate more rare mutations [12].

When used as monotherapy as the product Kalydeco, ivacaftor is indicated for the managmenet of CF in patients age 2 years and older who have a mutation in the CFTR gene that is responsive to ivacaftor potentiation (see above list of susceptible mutations).

When used in combination with the drug Lumacaftor as the product Orkambi, ivacaftor is indicated for the management of CF patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene.

Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms [4].

Ivacaftor is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012 and by Health Canada on November 26, 2012.

Structure
Thumb
Synonyms
  • Ivacaftorum
  • N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
External IDs
VX 770 / VX-770 / VX770
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
KalydecoTablet150 mgOralVertex Pharmaceuticals Incorporated2012-11-27Not applicableCanada
KalydecoTablet, film coated150 mg/1OralVertex Pharmaceuticals Incorporated2012-01-31Not applicableUs
KalydecoGranule50 mgOralVertex Pharmaceuticals Incorporated2015-09-14Not applicableCanada
KalydecoGranule50 mg/1OralVertex Pharmaceuticals Incorporated2015-03-23Not applicableUs
KalydecoGranule75 mgOralVertex Pharmaceuticals Incorporated2015-09-14Not applicableCanada
KalydecoGranule75 mg/1OralVertex Pharmaceuticals Incorporated2015-03-23Not applicableUs
International/Other Brands
Kalydeco
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
OrkambiIvacaftor (125 mg/1) + Lumacaftor (200 mg/1)Tablet, film coatedOralVertex Pharmaceuticals Incorporated2015-07-06Not applicableUs
OrkambiIvacaftor (125 mg) + Lumacaftor (200 mg)Tablet, film coatedOralVertex Pharmaceuticals (Europe) Ltd2015-11-19Not applicableEu
OrkambiIvacaftor (125 mg) + Lumacaftor (100 mg)TabletOralVertex Pharmaceuticals Incorporated2017-05-03Not applicableCanada
OrkambiIvacaftor (125 mg/1) + Lumacaftor (100 mg/1)Tablet, film coatedOralVertex Pharmaceuticals Incorporated2016-10-03Not applicableUs
OrkambiIvacaftor (125 mg) + Lumacaftor (200 mg)Tablet, film coatedOralVertex Pharmaceuticals (Europe) Ltd2015-11-19Not applicableEu
OrkambiIvacaftor (125 mg) + Lumacaftor (200 mg)Tablet, film coatedOralVertex Pharmaceuticals (Europe) Ltd2015-11-19Not applicableEu
OrkambiIvacaftor (125 mg) + Lumacaftor (200 mg)TabletOralVertex Pharmaceuticals Incorporated2016-01-27Not applicableCanada
Categories
UNII
1Y740ILL1Z
CAS number
873054-44-5
Weight
Average: 392.4907
Monoisotopic: 392.209992772
Chemical Formula
C24H28N2O3
InChI Key
PURKAOJPTOLRMP-UHFFFAOYSA-N
InChI
InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)
IUPAC Name
N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
SMILES
CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C

Pharmacology

Indication

When used as monotherapy as the product Kalydeco, ivacaftor is indicated for the managmenet of CF in patients age 2 years and older who have a mutation in the CFTR gene that is responsive to ivacaftor potentiation. Ivacaftor received expanded approval in May 2017 for the following 33 CFTR mutations: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, and G1349D [12].

When used in combination with the drug Lumacaftor as the product Orkambi, ivacaftor is indicated for the management of CF patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene.

Structured Indications
Pharmacodynamics

Results from clinical trials indicated that treatment with ivacaftor results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, reduced sweat chloride, increased weight gain, and improvements in CF symptoms and quality of life [FDA Label].

Ivacaftor was not found to increase the QTc interval to any clinically relevant extent [FDA Label].

Mechanism of action

Ivacaftor exerts its effect by acting as a potentiator of the CFTR protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes [5, 6]. Ivacaftor improves CF symptoms and underlying disease pathology by potentiating the channel open probability (or gating) of CFTR protein in patients with impaired CFTR gating mechanisms. The overall level of ivacaftor-mediated CFTR chloride transport is dependent on the amount of CFTR protein at the cell surface and how responsive a particular mutant CFTR protein is to ivacaftor potentiation [FDA Label].

TargetActionsOrganism
ACystic fibrosis transmembrane conductance regulator
potentiator
Human
Absorption

Following administration of ivacaftor with fat containing foods, peak plasma concentrations were reached at 4 hours (Tmax) with a maximum concentration (Cmax) of 768 ng/mL and AUC of 10600 ng * hr/mL. It's recommended that ivacaftor should be taken with fat-containing foods as they increase absorption by approximately 2.5- to 4-fold [FDA Label].

Volume of distribution

After oral administration of 150 mg every 12 hours for 7 days to healthy volunteers in a fed state, the mean (±SD) for apparent volume of distribution was 353 (122) L [FDA Label].

Protein binding

Ivacaftor is approximately 99% bound to plasma proteins, primarily to alpha 1-acid glycoprotein and albumin. Ivacaftor does not bind to human red blood cells [FDA Label].

Metabolism

Ivacaftor is extensively metabolized in humans. In vitro and clinical studies indicate that ivacaftor is primarily metabolized by CYP3A. M1 and M6 are the two major metabolites of ivacaftor in humans. M1 has approximately one-sixth the potency of ivacaftor and is considered pharmacologically active. M6 has less than one-fiftieth the potency of ivacaftor and is not considered pharmacologically active [FDA Label].

Route of elimination

Following oral administration, the majority of ivacaftor (87.8%) is eliminated in the feces after metabolic conversion. The major metabolites M1 and M6 accounted for approximately 65% of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of ivacaftor as unchanged parent [FDA Label].

Half life

The apparent terminal half-life was approximately 12 hours following a single dose [FDA Label].

Clearance

The CL/F (SD) for the 150 mg dose was 17.3 (8.4) L/hr in healthy subjects [FDA Label].

Toxicity

There have been no reports of overdose with Ivacaftor. The highest single dose used in a clinical study was 800 mg in a solution formulation without any treatment-related adverse events.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cystic fibrosis transmembrane conductance regulator---(A;A) / (A;G)A allele (G > A), double homozygoteEffect Directly StudiedPatients who carry this polymorphism in CFTR will respond to ivacaftor therapy.Details

Interactions

Drug Interactions
DrugInteractionDrug group
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Ivacaftor.Approved
AbirateroneThe serum concentration of Abiraterone can be increased when it is combined with Ivacaftor.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Ivacaftor.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Ivacaftor.Approved
AdinazolamThe serum concentration of Adinazolam can be increased when it is combined with Ivacaftor.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ivacaftor.Approved
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Ivacaftor.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Ivacaftor.Approved
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Ivacaftor.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Ivacaftor.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Ivacaftor.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be increased when it is combined with Ivacaftor.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Ivacaftor.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be increased when it is combined with Ivacaftor.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Ivacaftor.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Ivacaftor.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Ivacaftor.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be increased when it is combined with Ivacaftor.Approved, Investigational
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Ivacaftor.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Ivacaftor.Approved
AmiodaroneThe serum concentration of Ivacaftor can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Ivacaftor.Approved
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Ivacaftor.Approved
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Ivacaftor.Approved
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Ivacaftor.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Ivacaftor.Approved
ApremilastThe serum concentration of Apremilast can be increased when it is combined with Ivacaftor.Approved, Investigational
AprepitantThe serum concentration of Ivacaftor can be increased when it is combined with Aprepitant.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be increased when it is combined with Ivacaftor.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Ivacaftor.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be increased when it is combined with Ivacaftor.Approved
AsenapineThe serum concentration of Asenapine can be increased when it is combined with Ivacaftor.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Ivacaftor.Approved, Withdrawn
AtazanavirThe serum concentration of Ivacaftor can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Ivacaftor can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Ivacaftor is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Ivacaftor.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ivacaftor.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be increased when it is combined with Ivacaftor.Approved
AzithromycinThe serum concentration of Azithromycin can be increased when it is combined with Ivacaftor.Approved
BanoxantroneThe serum concentration of Banoxantrone can be increased when it is combined with Ivacaftor.Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Ivacaftor.Approved
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Ivacaftor.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Ivacaftor.Approved
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Ivacaftor.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be increased when it is combined with Ivacaftor.Approved
BicalutamideThe serum concentration of Bicalutamide can be increased when it is combined with Ivacaftor.Approved
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Ivacaftor.Approved
BoceprevirThe serum concentration of Ivacaftor can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Ivacaftor can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Ivacaftor.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ivacaftor.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ivacaftor.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Ivacaftor.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Ivacaftor.Approved
BrivaracetamThe serum concentration of Brivaracetam can be increased when it is combined with Ivacaftor.Approved, Investigational
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Ivacaftor.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Ivacaftor.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Ivacaftor.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Ivacaftor.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Ivacaftor.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Ivacaftor.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be increased when it is combined with Ivacaftor.Approved
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Ivacaftor.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Ivacaftor.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Ivacaftor.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Ivacaftor.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Ivacaftor.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Ivacaftor.Approved
CalcitriolThe serum concentration of Calcitriol can be increased when it is combined with Ivacaftor.Approved, Nutraceutical
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Ivacaftor.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Ivacaftor.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be increased when it is combined with Ivacaftor.Approved
CariprazineThe serum concentration of Cariprazine can be increased when it is combined with Ivacaftor.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Ivacaftor.Approved, Investigational
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Ivacaftor.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Ivacaftor.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Ivacaftor.Approved, Vet Approved
CeritinibThe serum concentration of Ivacaftor can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ivacaftor.Withdrawn
CevimelineThe serum concentration of Cevimeline can be increased when it is combined with Ivacaftor.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be increased when it is combined with Ivacaftor.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Ivacaftor.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Ivacaftor.Approved, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be increased when it is combined with Ivacaftor.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Ivacaftor.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Ivacaftor.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Ivacaftor.Approved, Nutraceutical
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Ivacaftor.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Ivacaftor.Approved
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Ivacaftor.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Ivacaftor.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Ivacaftor.Approved
ClarithromycinThe serum concentration of Ivacaftor can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Ivacaftor can be increased when it is combined with Clemastine.Approved
ClindamycinThe serum concentration of Clindamycin can be increased when it is combined with Ivacaftor.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Ivacaftor.Approved, Illicit
ClofazimineThe serum concentration of Clofazimine can be increased when it is combined with Ivacaftor.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be increased when it is combined with Ivacaftor.Approved, Investigational
clomethiazoleThe serum concentration of clomethiazole can be increased when it is combined with Ivacaftor.Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Ivacaftor.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be increased when it is combined with Ivacaftor.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Ivacaftor.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Ivacaftor.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Ivacaftor.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be increased when it is combined with Ivacaftor.Approved, Illicit
ClotrimazoleThe serum concentration of Ivacaftor can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Ivacaftor.Approved
CobicistatThe serum concentration of Ivacaftor can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Cocaine can be increased when it is combined with Ivacaftor.Approved, Illicit
CodeineThe serum concentration of Codeine can be increased when it is combined with Ivacaftor.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ivacaftor.Approved
ConivaptanThe serum concentration of Ivacaftor can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Ivacaftor.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Ivacaftor.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Ivacaftor.Approved
CrizotinibThe serum concentration of Ivacaftor can be increased when it is combined with Crizotinib.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ivacaftor.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be increased when it is combined with Ivacaftor.Approved, Investigational
CyclosporineThe serum concentration of Ivacaftor can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Ivacaftor.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ivacaftor.Approved
DabrafenibThe serum concentration of Ivacaftor can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Ivacaftor.Approved
DantroleneThe serum concentration of Dantrolene can be increased when it is combined with Ivacaftor.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Ivacaftor.Approved
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Ivacaftor.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Ivacaftor.Approved, Investigational
DarunavirThe serum concentration of Ivacaftor can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Ivacaftor.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Ivacaftor.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Ivacaftor.Approved
DeferasiroxThe serum concentration of Ivacaftor can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe serum concentration of Deflazacort can be increased when it is combined with Ivacaftor.Approved
DelavirdineThe serum concentration of Ivacaftor can be increased when it is combined with Delavirdine.Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be increased when it is combined with Ivacaftor.Approved
DeutetrabenazineThe serum concentration of Deutetrabenazine can be increased when it is combined with Ivacaftor.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Ivacaftor.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe serum concentration of Dexchlorpheniramine maleate can be increased when it is combined with Ivacaftor.Approved
DexlansoprazoleThe serum concentration of Dexlansoprazole can be increased when it is combined with Ivacaftor.Approved
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Ivacaftor.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be increased when it is combined with Ivacaftor.Approved, Illicit, Investigational, Withdrawn
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ivacaftor.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Ivacaftor.Approved, Vet Approved
DienogestThe serum concentration of Dienogest can be increased when it is combined with Ivacaftor.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Ivacaftor.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ivacaftor.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be increased when it is combined with Ivacaftor.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ivacaftor.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ivacaftor.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Ivacaftor.Experimental
DihydroergotamineThe serum concentration of Ivacaftor can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Ivacaftor can be increased when it is combined with Diltiazem.Approved
DisopyramideThe serum concentration of Disopyramide can be increased when it is combined with Ivacaftor.Approved
DisulfiramThe serum concentration of Disulfiram can be increased when it is combined with Ivacaftor.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Ivacaftor.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Ivacaftor.Approved
DolasetronThe serum concentration of Dolasetron can be increased when it is combined with Ivacaftor.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ivacaftor.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be increased when it is combined with Ivacaftor.Approved
DorzolamideThe serum concentration of Dorzolamide can be increased when it is combined with Ivacaftor.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Ivacaftor.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ivacaftor.Approved, Investigational
DoxycyclineThe serum concentration of Ivacaftor can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Ivacaftor.Approved, Illicit
DronedaroneThe serum concentration of Ivacaftor can be increased when it is combined with Dronedarone.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Ivacaftor.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Ivacaftor.Approved
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Ivacaftor.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Ivacaftor.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Ivacaftor.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Ivacaftor.Approved
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Ivacaftor.Approved
EnalaprilThe serum concentration of Enalapril can be increased when it is combined with Ivacaftor.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Ivacaftor.Approved
EnzalutamideThe serum concentration of Ivacaftor can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Ivacaftor.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Ivacaftor.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be increased when it is combined with Ivacaftor.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ivacaftor.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Ivacaftor.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Ivacaftor.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ivacaftor.Approved, Investigational
ErythromycinThe serum concentration of Ivacaftor can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Ivacaftor.Approved, Investigational
EsomeprazoleThe serum concentration of Esomeprazole can be increased when it is combined with Ivacaftor.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Ivacaftor.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Ivacaftor.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be increased when it is combined with Ivacaftor.Approved, Investigational
EstramustineThe serum concentration of Estramustine can be increased when it is combined with Ivacaftor.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be increased when it is combined with Ivacaftor.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Ivacaftor.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Ivacaftor.Approved
EszopicloneThe serum concentration of Eszopiclone can be increased when it is combined with Ivacaftor.Approved
EthanolThe serum concentration of Ethanol can be increased when it is combined with Ivacaftor.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ivacaftor.Approved
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Ivacaftor.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Ivacaftor.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Ivacaftor.Approved
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Ivacaftor.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Ivacaftor.Approved
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Ivacaftor.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Ivacaftor.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ivacaftor.Approved
ExemestaneThe serum concentration of Exemestane can be increased when it is combined with Ivacaftor.Approved, Investigational
FamciclovirThe serum concentration of Famciclovir can be increased when it is combined with Ivacaftor.Approved
FelbamateThe serum concentration of Felbamate can be increased when it is combined with Ivacaftor.Approved
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Ivacaftor.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be increased when it is combined with Ivacaftor.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Ivacaftor.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Ivacaftor.Approved
FinasterideThe serum concentration of Finasteride can be increased when it is combined with Ivacaftor.Approved
FingolimodThe serum concentration of Fingolimod can be increased when it is combined with Ivacaftor.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Ivacaftor.Approved
FluconazoleThe serum concentration of Ivacaftor can be increased when it is combined with Fluconazole.Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Ivacaftor.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Ivacaftor.Approved, Illicit
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Ivacaftor.Approved
FluoxetineThe serum concentration of Fluoxetine can be increased when it is combined with Ivacaftor.Approved, Vet Approved
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Ivacaftor.Approved, Illicit
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Ivacaftor.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ivacaftor.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Ivacaftor.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Ivacaftor.Approved
FluvoxamineThe serum concentration of Ivacaftor can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Ivacaftor can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ivacaftor can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Ivacaftor can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe serum concentration of Fulvestrant can be increased when it is combined with Ivacaftor.Approved, Investigational
Fusidic AcidThe serum concentration of Ivacaftor can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe serum concentration of Galantamine can be increased when it is combined with Ivacaftor.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Ivacaftor.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be increased when it is combined with Ivacaftor.Approved
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Ivacaftor.Approved
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Ivacaftor.Approved
GranisetronThe serum concentration of Granisetron can be increased when it is combined with Ivacaftor.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Ivacaftor.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Ivacaftor.Investigational, Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Ivacaftor.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Ivacaftor.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Ivacaftor.Approved
HalothaneThe serum concentration of Halothane can be increased when it is combined with Ivacaftor.Approved, Vet Approved
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Ivacaftor.Approved
HistamineThe serum concentration of Histamine can be increased when it is combined with Ivacaftor.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Ivacaftor.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Ivacaftor.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be increased when it is combined with Ivacaftor.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Ivacaftor.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Ivacaftor.Approved
IcotinibThe serum concentration of Icotinib can be increased when it is combined with Ivacaftor.Approved, Investigational
IdelalisibThe serum concentration of Ivacaftor can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Ivacaftor.Approved
IloperidoneThe serum concentration of Iloperidone can be increased when it is combined with Ivacaftor.Approved
ImatinibThe serum concentration of Ivacaftor can be increased when it is combined with Imatinib.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Ivacaftor.Approved, Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Ivacaftor.Approved
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Ivacaftor.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Ivacaftor.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Ivacaftor.Approved
IndinavirThe serum concentration of Ivacaftor can be increased when it is combined with Indinavir.Approved
Ipratropium bromideThe serum concentration of Ipratropium bromide can be increased when it is combined with Ivacaftor.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Ivacaftor.Approved, Investigational
IsavuconazoniumThe serum concentration of Ivacaftor can be increased when it is combined with Isavuconazonium.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Ivacaftor.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Ivacaftor.Approved
IsradipineThe serum concentration of Ivacaftor can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Ivacaftor can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Ivacaftor.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Ivacaftor.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Ivacaftor.Approved
KetamineThe serum concentration of Ketamine can be increased when it is combined with Ivacaftor.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Ivacaftor.Approved
KetobemidoneThe serum concentration of Ketobemidone can be increased when it is combined with Ivacaftor.Approved, Investigational
KetoconazoleThe serum concentration of Ivacaftor can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Ivacaftor.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Ivacaftor.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be increased when it is combined with Ivacaftor.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Ivacaftor.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Ivacaftor.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Ivacaftor.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be increased when it is combined with Ivacaftor.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Ivacaftor.Approved, Investigational
LevocetirizineThe serum concentration of Levocetirizine can be increased when it is combined with Ivacaftor.Approved
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Ivacaftor.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Ivacaftor.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Ivacaftor.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be increased when it is combined with Ivacaftor.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Ivacaftor.Approved, Vet Approved
LisurideThe serum concentration of Lisuride can be increased when it is combined with Ivacaftor.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Ivacaftor.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Ivacaftor.Approved
LopinavirThe serum concentration of Ivacaftor can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Ivacaftor.Approved
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Ivacaftor.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Ivacaftor.Approved
LovastatinThe serum concentration of Ivacaftor can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Ivacaftor can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Ivacaftor.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Ivacaftor.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Ivacaftor.Illicit, Investigational, Withdrawn
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Ivacaftor.Approved
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Ivacaftor.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Ivacaftor.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ivacaftor.Approved, Investigational
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Ivacaftor.Approved
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Ivacaftor.Approved, Vet Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Ivacaftor.Experimental
MethadoneThe serum concentration of Methadone can be increased when it is combined with Ivacaftor.Approved
MethaqualoneThe serum concentration of Methaqualone can be increased when it is combined with Ivacaftor.Illicit, Withdrawn
MethoxsalenThe serum concentration of Methoxsalen can be increased when it is combined with Ivacaftor.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Ivacaftor.Approved, Investigational, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ivacaftor.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ivacaftor.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be increased when it is combined with Ivacaftor.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Ivacaftor.Approved
MetronidazoleThe serum concentration of Metronidazole can be increased when it is combined with Ivacaftor.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Ivacaftor.Experimental
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Ivacaftor.Approved
MianserinThe serum concentration of Mianserin can be increased when it is combined with Ivacaftor.Approved, Investigational
MibefradilThe serum concentration of Mibefradil can be increased when it is combined with Ivacaftor.Investigational, Withdrawn
MiconazoleThe serum concentration of Miconazole can be increased when it is combined with Ivacaftor.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ivacaftor.Approved, Illicit
MidostaurinThe serum concentration of Midostaurin can be increased when it is combined with Ivacaftor.Approved
MifepristoneThe serum concentration of Ivacaftor can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Ivacaftor.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Ivacaftor.Approved
MitotaneThe serum concentration of Ivacaftor can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Modafinil can be increased when it is combined with Ivacaftor.Approved, Investigational
MontelukastThe serum concentration of Montelukast can be increased when it is combined with Ivacaftor.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Ivacaftor.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ivacaftor.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ivacaftor.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Ivacaftor.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Ivacaftor.Approved, Investigational
NefazodoneThe serum concentration of Ivacaftor can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Ivacaftor can be increased when it is combined with Nelfinavir.Approved
NeratinibThe serum concentration of Neratinib can be increased when it is combined with Ivacaftor.Approved, Investigational
NetupitantThe serum concentration of Ivacaftor can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Ivacaftor can be increased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Ivacaftor.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Ivacaftor.Approved, Investigational
NicotineThe serum concentration of Nicotine can be increased when it is combined with Ivacaftor.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Ivacaftor.Approved
NilotinibThe serum concentration of Ivacaftor can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Ivacaftor.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Ivacaftor.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ivacaftor.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Ivacaftor.Approved
NitrazepamThe serum concentration of Nitrazepam can be increased when it is combined with Ivacaftor.Approved
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Ivacaftor.Approved, Investigational
NorethisteroneThe serum concentration of Norethisterone can be increased when it is combined with Ivacaftor.Approved
NorgestrelThe serum concentration of Norgestrel can be increased when it is combined with Ivacaftor.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Ivacaftor.Approved
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Ivacaftor.Investigational
OlaparibThe serum concentration of Ivacaftor can be increased when it is combined with Olaparib.Approved
OlopatadineThe serum concentration of Olopatadine can be increased when it is combined with Ivacaftor.Approved
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Ivacaftor.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Ivacaftor.Approved
OrphenadrineThe serum concentration of Orphenadrine can be increased when it is combined with Ivacaftor.Approved
OsimertinibThe serum concentration of Ivacaftor can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Ivacaftor.Approved
OxazepamThe serum concentration of Oxazepam can be increased when it is combined with Ivacaftor.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Ivacaftor.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Ivacaftor.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be increased when it is combined with Ivacaftor.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Ivacaftor.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Ivacaftor.Approved
PalonosetronThe serum concentration of Palonosetron can be increased when it is combined with Ivacaftor.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Ivacaftor.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Ivacaftor.Approved
ParamethadioneThe serum concentration of Paramethadione can be increased when it is combined with Ivacaftor.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Ivacaftor.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Ivacaftor.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Ivacaftor.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Ivacaftor.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ivacaftor.Approved
PentamidineThe serum concentration of Pentamidine can be increased when it is combined with Ivacaftor.Approved
PentobarbitalThe serum concentration of Ivacaftor can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelThe serum concentration of Perampanel can be increased when it is combined with Ivacaftor.Approved
PergolideThe serum concentration of Pergolide can be increased when it is combined with Ivacaftor.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Ivacaftor.Approved, Investigational
PermethrinThe serum concentration of Permethrin can be increased when it is combined with Ivacaftor.Approved, Investigational
PerospironeThe serum concentration of Perospirone can be increased when it is combined with Ivacaftor.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Ivacaftor.Approved
PethidineThe serum concentration of Pethidine can be increased when it is combined with Ivacaftor.Approved
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Ivacaftor.Withdrawn
PhenobarbitalThe serum concentration of Ivacaftor can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be increased when it is combined with Ivacaftor.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Ivacaftor.Approved, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Ivacaftor.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be increased when it is combined with Ivacaftor.Approved
PimecrolimusThe serum concentration of Pimecrolimus can be increased when it is combined with Ivacaftor.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Ivacaftor.Approved
PinacidilThe serum concentration of Pinacidil can be increased when it is combined with Ivacaftor.Withdrawn
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Ivacaftor.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Ivacaftor.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ivacaftor.Approved
PodofiloxThe serum concentration of Podofilox can be increased when it is combined with Ivacaftor.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ivacaftor.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Ivacaftor.Approved
PosaconazoleThe serum concentration of Ivacaftor can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Prasterone can be increased when it is combined with Ivacaftor.Approved, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be increased when it is combined with Ivacaftor.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ivacaftor.Approved
PrazepamThe serum concentration of Prazepam can be increased when it is combined with Ivacaftor.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Ivacaftor.Approved, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ivacaftor.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Ivacaftor.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be increased when it is combined with Ivacaftor.Approved
PrimidoneThe serum concentration of Ivacaftor can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Ivacaftor.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Ivacaftor.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be increased when it is combined with Ivacaftor.Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Ivacaftor.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Ivacaftor.Approved
PropofolThe serum concentration of Propofol can be increased when it is combined with Ivacaftor.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Ivacaftor.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Ivacaftor.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ivacaftor.Approved
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Ivacaftor.Approved
QuazepamThe serum concentration of Quazepam can be increased when it is combined with Ivacaftor.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Ivacaftor.Approved
QuinacrineThe serum concentration of Quinacrine can be increased when it is combined with Ivacaftor.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Ivacaftor.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Ivacaftor.Approved
RabeprazoleThe serum concentration of Rabeprazole can be increased when it is combined with Ivacaftor.Approved, Investigational
RaloxifeneThe serum concentration of Raloxifene can be increased when it is combined with Ivacaftor.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Ivacaftor.Approved, Investigational
RanolazineThe serum concentration of Ivacaftor can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Reboxetine can be increased when it is combined with Ivacaftor.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Ivacaftor.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Ivacaftor.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Ivacaftor.Approved
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Ivacaftor.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Ivacaftor.Approved
RifapentineThe serum concentration of Ivacaftor can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ivacaftor.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Ivacaftor.Approved
RimonabantThe serum concentration of Rimonabant can be increased when it is combined with Ivacaftor.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Ivacaftor.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Ivacaftor.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Ivacaftor.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Ivacaftor.Approved
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Ivacaftor.Investigational, Withdrawn
RolapitantThe serum concentration of Rolapitant can be increased when it is combined with Ivacaftor.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ivacaftor.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Ivacaftor.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Ivacaftor.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ivacaftor.Approved
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Ivacaftor.Approved
RoxithromycinThe serum concentration of Roxithromycin can be increased when it is combined with Ivacaftor.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Ivacaftor.Approved, Investigational
RupatadineThe serum concentration of Rupatadine can be increased when it is combined with Ivacaftor.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Ivacaftor.Approved
SafinamideThe serum concentration of Safinamide can be increased when it is combined with Ivacaftor.Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Ivacaftor.Approved
SaquinavirThe serum concentration of Ivacaftor can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Ivacaftor.Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Ivacaftor.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Ivacaftor.Approved
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Ivacaftor.Approved
SertindoleThe serum concentration of Sertindole can be increased when it is combined with Ivacaftor.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Sertraline can be increased when it is combined with Ivacaftor.Approved
SevofluraneThe serum concentration of Sevoflurane can be increased when it is combined with Ivacaftor.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be increased when it is combined with Ivacaftor.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Ivacaftor can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ivacaftor.Approved
SiltuximabThe serum concentration of Ivacaftor can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ivacaftor can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ivacaftor.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Ivacaftor.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Ivacaftor.Approved, Investigational
SolifenacinThe serum concentration of Solifenacin can be increased when it is combined with Ivacaftor.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Ivacaftor.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Ivacaftor.Approved, Investigational
SpiramycinThe serum concentration of Spiramycin can be increased when it is combined with Ivacaftor.Approved
St. John's WortThe serum concentration of Ivacaftor can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Ivacaftor can be increased when it is combined with Stiripentol.Approved
SufentanilThe serum concentration of Sufentanil can be increased when it is combined with Ivacaftor.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be increased when it is combined with Ivacaftor.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be increased when it is combined with Ivacaftor.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be increased when it is combined with Ivacaftor.Approved
SulfisoxazoleThe serum concentration of Ivacaftor can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Ivacaftor.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be increased when it is combined with Ivacaftor.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Ivacaftor.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Ivacaftor.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Ivacaftor.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Ivacaftor.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Ivacaftor.Approved, Investigational
TasosartanThe serum concentration of Tasosartan can be increased when it is combined with Ivacaftor.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be increased when it is combined with Ivacaftor.Experimental
TelaprevirThe serum concentration of Ivacaftor can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Ivacaftor can be increased when it is combined with Telithromycin.Approved
TemazepamThe serum concentration of Temazepam can be increased when it is combined with Ivacaftor.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Ivacaftor.Approved
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Ivacaftor.Approved
TerbinafineThe serum concentration of Terbinafine can be increased when it is combined with Ivacaftor.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Ivacaftor.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Ivacaftor.Experimental
TesmilifeneThe serum concentration of Tesmilifene can be increased when it is combined with Ivacaftor.Investigational
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Ivacaftor.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Ivacaftor.Approved, Vet Approved
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Ivacaftor.Approved
ThiotepaThe serum concentration of Thiotepa can be increased when it is combined with Ivacaftor.Approved
TiagabineThe serum concentration of Tiagabine can be increased when it is combined with Ivacaftor.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Ivacaftor.Approved
TiclopidineThe serum concentration of Ivacaftor can be increased when it is combined with Ticlopidine.Approved
TinidazoleThe serum concentration of Tinidazole can be increased when it is combined with Ivacaftor.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be increased when it is combined with Ivacaftor.Approved
TipranavirThe serum concentration of Tipranavir can be increased when it is combined with Ivacaftor.Approved, Investigational
TocilizumabThe serum concentration of Ivacaftor can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Ivacaftor.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Ivacaftor.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ivacaftor.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ivacaftor.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Ivacaftor.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Ivacaftor.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Ivacaftor.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Ivacaftor.Approved
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Ivacaftor.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Ivacaftor.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Ivacaftor.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Ivacaftor.Approved
TrimethadioneThe serum concentration of Trimethadione can be increased when it is combined with Ivacaftor.Approved
TrimethoprimThe serum concentration of Trimethoprim can be increased when it is combined with Ivacaftor.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Ivacaftor.Approved
TroglitazoneThe serum concentration of Troglitazone can be increased when it is combined with Ivacaftor.Investigational, Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be increased when it is combined with Ivacaftor.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Ivacaftor.Approved, Experimental
UdenafilThe serum concentration of Udenafil can be increased when it is combined with Ivacaftor.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ivacaftor.Approved
ValbenazineThe serum concentration of Valbenazine can be increased when it is combined with Ivacaftor.Approved, Investigational
ValdecoxibThe serum concentration of Valdecoxib can be increased when it is combined with Ivacaftor.Investigational, Withdrawn
VandetanibThe serum concentration of Vandetanib can be increased when it is combined with Ivacaftor.Approved
VanoxerineThe serum concentration of Vanoxerine can be increased when it is combined with Ivacaftor.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Ivacaftor.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Ivacaftor.Approved
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Ivacaftor.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Ivacaftor.Approved
VenlafaxineThe serum concentration of Ivacaftor can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Ivacaftor can be increased when it is combined with Verapamil.Approved
VicrivirocThe serum concentration of Vicriviroc can be increased when it is combined with Ivacaftor.Investigational
VilanterolThe serum concentration of Vilanterol can be increased when it is combined with Ivacaftor.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Ivacaftor.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Ivacaftor.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ivacaftor.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Ivacaftor.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Ivacaftor.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Ivacaftor.Approved
VoriconazoleThe serum concentration of Ivacaftor can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Ivacaftor.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Ivacaftor.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Ivacaftor.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Ivacaftor.Approved, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be increased when it is combined with Ivacaftor.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Ivacaftor.Approved, Investigational
ZaleplonThe serum concentration of Zaleplon can be increased when it is combined with Ivacaftor.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Ivacaftor.Approved
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Ivacaftor.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ivacaftor can be increased when it is combined with Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Ivacaftor.Approved
ZomepiracThe serum concentration of Zomepirac can be increased when it is combined with Ivacaftor.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Ivacaftor.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Ivacaftor.Approved
Food Interactions
  • Exposure increases 2- to 4- fold when given with a high fat meal. It is recommended that ivacaftor be given this way.

References

General References
  1. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordonez CL, Campbell PW, Ashlock MA, Ramsey BW: Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825. [PubMed:21083385]
  2. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordonez C, Elborn JS: A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185. [PubMed:22047557]
  3. Eckford PD, Li C, Ramjeesingh M, Bear CE: Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem. 2012 Oct 26;287(44):36639-49. doi: 10.1074/jbc.M112.393637. Epub 2012 Aug 31. [PubMed:22942289]
  4. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, Zhou J, McCartney J, Arumugam V, Decker C, Yang J, Young C, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu P: Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18825-30. doi: 10.1073/pnas.0904709106. Epub 2009 Oct 21. [PubMed:19846789]
  5. Saint-Criq V, Gray MA: Role of CFTR in epithelial physiology. Cell Mol Life Sci. 2017 Jan;74(1):93-115. doi: 10.1007/s00018-016-2391-y. Epub 2016 Oct 6. [PubMed:27714410]
  6. Kunzelmann K, Mall M: Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics. Am J Respir Med. 2003;2(4):299-309. [PubMed:14719996]
  7. MacDonald KD, McKenzie KR, Zeitlin PL: Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation. Paediatr Drugs. 2007;9(1):1-10. [PubMed:17291132]
  8. Fraser-Pitt D, O'Neil D: Cystic fibrosis - a multiorgan protein misfolding disease. Future Sci OA. 2015 Sep 1;1(2):FSO57. doi: 10.4155/fso.15.57. eCollection 2015 Sep. [PubMed:28031875]
  9. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP Jr, Urrutia A, Joubran J, Seepersaud S, Sussky K, Hoffman BJ, Van Goor F: Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012 May;11(3):237-45. doi: 10.1016/j.jcf.2011.12.005. Epub 2012 Jan 30. [PubMed:22293084]
  10. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordonez CL, Geller DE: Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012 Sep;142(3):718-724. doi: 10.1378/chest.11-2672. [PubMed:22383668]
  11. Mayer M: Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'. Evid Based Med. 2016 Jun;21(3):83-6. doi: 10.1136/ebmed-2015-110325. Epub 2015 Dec 30. [PubMed:26718821]
  12. FDA Approval Update May 17, 2017 [Link]
External Links
Human Metabolome Database
HMDB15705
KEGG Drug
D09916
PubChem Compound
16220172
PubChem Substance
175427103
ChemSpider
17347474
BindingDB
50032693
ChEBI
66901
ChEMBL
CHEMBL2010601
PharmGKB
PA165950341
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ivacaftor
ATC Codes
R07AX30 — Ivacaftor and lumacaftorR07AX02 — Ivacaftor
AHFS Codes
  • 48:14.12 — Cystic Fibrosis Transmembrane Conductance Regulator Potentiators
FDA label
Download (239 KB)
MSDS
Download (353 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingDiagnosticCystic Fibrosis (CF)1
0CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1CompletedNot AvailableCystic Fibrosis (CF)1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedTreatmentCystic Fibrosis (CF)7
1CompletedTreatmentIn Development for Cystic Fibrosis2
1RecruitingTreatmentCystic Fibrosis (CF)1
1, 2RecruitingTreatmentCystic Fibrosis (CF)1
2CompletedTreatmentCystic Fibrosis (CF)11
2RecruitingTreatmentChronic Bronchitis / Chronic Obstructive Pulmonary Disease (COPD)1
2RecruitingTreatmentCystic Fibrosis (CF)3
2RecruitingTreatmentPrimary Ciliary Dyskinesia (PCD)1
2TerminatedTreatmentCystic Fibrosis (CF)2
3Active Not RecruitingTreatmentCystic Fibrosis (CF)2
3CompletedTreatmentAdvanced Lung Disease / Cystic Fibrosis (CF)1
3CompletedTreatmentCystic Fibrosis (CF)15
3CompletedTreatmentCystic Fibrosis, Homozygous for the F508del CFTR Mutation2
3CompletedTreatmentCystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation1
3Enrolling by InvitationTreatmentCystic Fibrosis (CF)2
3RecruitingTreatmentCystic Fibrosis (CF)5
3TerminatedTreatmentCystic Fibrosis (CF)1
4Active Not RecruitingBasic ScienceCystic Fibrosis (CF)1
4Active Not RecruitingOtherCystic Fibrosis (CF)1
4CompletedTreatmentCystic Fibrosis (CF)1
4Not Yet RecruitingTreatmentChronic Bronchitis1
4TerminatedTreatmentCystic Fibrosis (CF)1
Not AvailableActive Not RecruitingNot AvailableCystic Fibrosis (CF)1
Not AvailableApproved for MarketingNot AvailableCystic Fibrosis (CF)1
Not AvailableAvailableNot AvailableCystic Fibrosis (CF)1
Not AvailableNot Yet RecruitingScreeningCystic Fibrosis (CF) / Diabetes2
Not AvailableRecruitingNot AvailableCystic Fibrosis (CF)1
Not AvailableUnknown StatusScreeningCystic Fibrosis (CF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
GranuleOral50 mg/1
GranuleOral50 mg
GranuleOral75 mg/1
GranuleOral75 mg
TabletOral150 mg
Tablet, film coatedOral150 mg/1
TabletOral
Tablet, film coatedOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8324242No2007-04-182027-04-18Us
US8354427No2006-07-062026-07-06Us
US8754224No2006-12-282026-12-28Us
US8410274No2006-12-282026-12-28Us
US7495103No2007-05-202027-05-20Us
US8741933No2006-11-082026-11-08Us
US8716338No2006-11-082026-11-08Us
US8846718No2008-12-042028-12-04Us
US8653103No2008-12-042028-12-04Us
US9216969No2006-11-082026-11-08Us
US8507534No2010-09-202030-09-20Us
US8993600No2010-12-112030-12-11Us
US8883206No2013-02-272033-02-27Us
US9670163No2006-12-282026-12-28Us
US9192606No2009-09-292029-09-29Us
US7973038No2006-11-082026-11-08Us
US9150552No2008-12-042028-12-04Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsoluble (<0.05 µg/mL)FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.002 mg/mLALOGPS
logP5ALOGPS
logP5.76ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)6.57ChemAxon
pKa (Strongest Basic)-0.95ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area78.43 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity118.68 m3·mol-1ChemAxon
Polarizability43.04 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9577
Blood Brain Barrier+0.6561
Caco-2 permeable-0.5608
P-glycoprotein substrateNon-substrate0.5474
P-glycoprotein inhibitor INon-inhibitor0.7677
P-glycoprotein inhibitor IINon-inhibitor0.7609
Renal organic cation transporterNon-inhibitor0.945
CYP450 2C9 substrateNon-substrate0.7374
CYP450 2D6 substrateNon-substrate0.8362
CYP450 3A4 substrateSubstrate0.5686
CYP450 1A2 substrateInhibitor0.5438
CYP450 2C9 inhibitorInhibitor0.6456
CYP450 2D6 inhibitorNon-inhibitor0.9469
CYP450 2C19 inhibitorNon-inhibitor0.6422
CYP450 3A4 inhibitorNon-inhibitor0.8404
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5791
Ames testNon AMES toxic0.8394
CarcinogenicityNon-carcinogens0.8149
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.2868 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9961
hERG inhibition (predictor II)Non-inhibitor0.819
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0079-1809000000-c0147e018d786aee606b

Taxonomy

Description
This compound belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Aromatic anilides
Alternative Parents
Quinoline-3-carboxamides / Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids and derivatives / Phenylpropanes / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Azacyclic compounds
show 5 more
Substituents
Aromatic anilide / Quinoline-3-carboxamide / Dihydroquinolone / Quinoline / Dihydroquinoline / Phenylpropane / Pyridine carboxylic acid or derivatives / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Pyridine
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
monocarboxylic acid amide, phenols, aromatic amide, quinolone (CHEBI:66901)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Pdz domain binding
Specific Function
Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter. Can inhibit the chloride channel activity of ANO...
Gene Name
CFTR
Uniprot ID
P13569
Uniprot Name
Cystic fibrosis transmembrane conductance regulator
Molecular Weight
168139.895 Da
References
  1. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP Jr, Urrutia A, Joubran J, Seepersaud S, Sussky K, Hoffman BJ, Van Goor F: Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012 May;11(3):237-45. doi: 10.1016/j.jcf.2011.12.005. Epub 2012 Jan 30. [PubMed:22293084]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Carrier
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Carrier
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da

Drug created on February 24, 2012 11:15 / Updated on November 19, 2017 20:34